389 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
NVO Novo Nordisk A/S $47.64 $114.84B Buy
Article Searches
Week In Review: Grifols Pays $1.9 Billion For 26% Stake In Shanghai RAAS https://seekingalpha.com/article/4247595-week-review-grifols-pays-1_9-billion-26-percent-stake-shanghai-raas?source=feed_sector_healthcare Mar 10, 2019 - Grifols, a Barcelona maker of plasma-based medicines, acquired a 26% stake in Shanghai RAAS, one of China's largest blood plasma companies, for $1.9 billion in a non-cash deal.Ambrx, a San Diego bioph
Are 46 Fortune Best Public Co's To Work At Worth Buying In 2019? https://seekingalpha.com/article/4247035-46-fortune-best-public-cos-work-worth-buying-2019?source=feed_all_articles Mar 07, 2019 - Fortune's annual survey of the 100 best companies to work for turned up 46 publicly owned entities. Here's another list to test our dog metrics.Top net-gainers CMCSA, GS, CPT, T, ABBV, COF, FDX, EHC,
Xeris: Looking For Entry Before PDUFA https://seekingalpha.com/article/4246895-xeris-looking-entry-pdufa?source=feed_sector_healthcare Mar 07, 2019 - Xeris Pharmaceuticals is awaiting FDA approval for their shelf-stable Gvoke HypoPen for the emergency treatment of acute hypoglycemia.The company's FDA PDUFA date is on June 10th and I want to start a
Investment Process Special (Part 1 Of 3): The Core Value Drivers With Novo Nordisk And W.W. Grainger https://seekingalpha.com/article/4246332-investment-process-special-part-1-3-core-value-drivers-novo-nordisk-w-w-grainger?source=feed_tag_etf_portfolio_strategy Mar 05, 2019 - The main drivers of value creation over time are growth and return on invested capital (in relation to cost of capital).The investing world has created investment styles such as growth and value, but
What's in the Cards for Aeterna (AEZS) This Earnings Season? http://www.zacks.com/stock/news/357560/whats-in-the-cards-for-aeterna-aezs-this-earnings-season?cid=CS-ZC-FT-357560 Mar 04, 2019 - Aeterna (AEZS) growth hormone deficiency test, Macrilen, to drive revenues in the fourth quarter.
Ophthotech's (OPHT) Q4 Loss Wider, Gene Therapy in Focus http://www.zacks.com/stock/news/357166/ophthotechs-opht-q4-loss-wider-gene-therapy-in-focus?cid=CS-ZC-FT-357166 Feb 27, 2019 - Ophthotech (OPHT) reports wider-than-expected loss in the fourth quarter. It boosts gene therapy pipeline through new agreements and acquisitions.
Pharma Stock Roundup: MRK Buys IMDZ, FDA Grants Priority Review to Some Candidates http://www.zacks.com/stock/news/356445/pharma-stock-roundup-mrk-buys-imdz-fda-grants-priority-review-to-some-candidates?cid=CS-ZC-FT-356445 Feb 22, 2019 - Merck (MRK) to buy Immune Design for $300 million. FDA grants priority review to regulatory applications filed by Merck, Roche (RHHBY) and AbbVie (ABBV).
Novo Nordisk Gets FDA Nod for Haemophilia Drug Esperoct http://www.zacks.com/stock/news/355654/novo-nordisk-gets-fda-nod-for-haemophilia-drug-esperoct?cid=CS-ZC-FT-355654 Feb 20, 2019 - Novo Nordisk (NVO) clinches the FDA approval for its biologics license application in favor of Esperoct to treat adults and children suffering haemophilia A.
Novo Nordisk Has Managed The Turnaround https://seekingalpha.com/article/4240750-novo-nordisk-managed-turnaround?source=feed_sector_healthcare Feb 13, 2019 - Novo Nordisk reported full year results for 2018, and while revenue was still stagnant, earning per share could grow 4%.Due to the launch of new products like Saxenda, Ozempic, and Oral Semaglutide, N
Seattle Genetics' Adcetris Gets EC Nod for Label Expansion http://www.zacks.com/stock/news/354019/seattle-genetics-adcetris-gets-ec-nod-for-label-expansion?cid=CS-ZC-FT-354019 Feb 12, 2019 - Seattle Genetics' (SGEN) partner, Takeda Pharmaceutical receives EC approval for Adcetris in combination with AVD to treat adults with previously untreated CD30+ stage IV cHL.

Pages: 123456...39

Page 1>

Related Companies

Name Exchange Price Mkt Cap
LLY Eli Lilly and Company NYSE $105.71 $113.53B
ABT Abbott Laboratories NYSE $67.67 $118.71B
SNY Sanofi NYSE $43.75 $109.14B
BMY Bristol-Myers Squibb Company NYSE $61.3 $100.03B
GSK GlaxoSmithKline PLC NYSE $39.21 $97.25B
Sector: Health Care > Industry: Major Pharmaceuticals
DeepLinks for Novo Nordisk A/S
NVO - Google Finance https://www.google.com/finance?q=NVO Industry related info and international coverage Summary News
NVO - Bloomberg http://www.bloomberg.com/research/stocks/snapshot/snapshot.asp?ticker=NVO Original news and commentary from Bloomberg Charts Financials with pensions Snapshot Earnings Transactions People Options